Woodline Partners LP Increases Stake in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

Woodline Partners LP increased its position in Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) by 239.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 488,756 shares of the company's stock after acquiring an additional 344,614 shares during the quarter. Woodline Partners LP owned about 1.20% of Vigil Neuroscience worth $831,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Cubist Systematic Strategies LLC boosted its stake in Vigil Neuroscience by 53.0% in the 4th quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company's stock worth $41,000 after purchasing an additional 8,358 shares during the period. Northern Trust Corp boosted its position in shares of Vigil Neuroscience by 29.0% during the 4th quarter. Northern Trust Corp now owns 64,737 shares of the company's stock valued at $110,000 after acquiring an additional 14,572 shares during the last quarter. Barclays PLC boosted its position in shares of Vigil Neuroscience by 43.6% during the 4th quarter. Barclays PLC now owns 64,049 shares of the company's stock valued at $109,000 after acquiring an additional 19,436 shares during the last quarter. Two Sigma Investments LP boosted its position in shares of Vigil Neuroscience by 44.0% during the 4th quarter. Two Sigma Investments LP now owns 136,920 shares of the company's stock valued at $233,000 after acquiring an additional 41,836 shares during the last quarter. Finally, Jane Street Group LLC bought a new position in shares of Vigil Neuroscience during the 4th quarter valued at approximately $83,000. 83.64% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently commented on VIGL. William Blair downgraded Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Jefferies Financial Group downgraded Vigil Neuroscience to a "hold" rating in a research report on Thursday, May 22nd. Mizuho downgraded Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 23rd. JMP Securities restated a "market perform" rating on shares of Vigil Neuroscience in a research report on Thursday, May 22nd. Finally, Wedbush downgraded Vigil Neuroscience from a "strong-buy" rating to a "hold" rating and lowered their price target for the stock from $13.00 to $8.00 in a research report on Thursday, May 22nd. Ten research analysts have rated the stock with a hold rating, According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $10.80.

Vigil Neuroscience Stock Performance

Shares of Vigil Neuroscience stock remained flat at $7.88 during trading on Friday. The stock had a trading volume of 1,210,695 shares, compared to its average volume of 659,578. The stock has a market cap of $367.78 million, a price-to-earnings ratio of -3.83 and a beta of 1.90. Vigil Neuroscience, Inc. has a 1 year low of $1.31 and a 1 year high of $7.95. The firm's 50-day moving average is $2.79 and its two-hundred day moving average is $2.44.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.04. On average, equities research analysts anticipate that Vigil Neuroscience, Inc. will post -2.07 earnings per share for the current fiscal year.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.